Login to Your Account


Probiotics get new name, advance in clinic trial

By Brian Orelli
Contributing Writer

Friday, February 7, 2014
Orphan-drug specialist, Sigma-Tau Pharmaceuticals Inc. is developing a new class of drugs: live biotherapeutics. As the name implies, Sigma-Tau’s drug candidate, STP206, is a live organism used to repopulate patients’ gastrointestinal tracks. “It’s essentially a probiotic produced in GMP quality,” Sigma-Tau’s CEO Dave Lemus told BioWorld Today.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription